Hong Kong — Pfizer is reviewing options including a sale of its women’s health portfolio as the US pharmaceutical giant seeks to focus on developing treatments with higher growth potential, according to people with knowledge of the matter. The drug maker is working with financial advisers to gauge the interest of potential buyers, the people said, asking not to be identified because the deliberations were private. A sale of the division, which has annual sales of roughly $1.2bn, could fetch about $2bn and draw bids from both private equity firms and rival pharmaceutical companies, they said. A spokesperson for Pfizer said the drug maker declined to comment on speculation. No final decision had been reached and the company may yet decide to retain the assets, which include menopause treatments such as Premarin, Prempro and Premphase, the people said. A divestment of the business would mean that Pfizer, which narrowed its full-year forecast in October amid manufacturing challenges wit...

BL Premium

This article is reserved for our subscribers.

A subscription helps you enjoy the best of our business content every day along with benefits such as exclusive Financial Times articles, ProfileData financial data, and digital access to the Sunday Times and Times Select.

Already subscribed? Simply sign in below.



Questions or problems? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now